Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says
August 11, 2015 7:58 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating but lowered his price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $41.00 (from $58.00) following yesterday's sell-off. The analyst said the move is overdone in their view.
Schmidt commented, "KPTI reported 2Q15 financial results and provided a pipeline update. Mgmt announced it... More
Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
August 10, 2015 7:41 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $90 thousand.
Financial Outlook
Based on current operating plans, Karyopharm expects that its existing... More
